Sarepta Therapeutics (SRPT) Short Interest Ratio & Short Volume $16.30 -0.45 (-2.66%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Sarepta Therapeutics Short Interest DataSarepta Therapeutics (SRPT) has a short interest of 14.86 million shares. This marks a 1.23% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.8, indicating that it would take 1.8 days of the average trading volume of 5.88 million shares to cover all short positions.Current Short Interest14,860,000 sharesPrevious Short Interest14,680,000 sharesChange Vs. Previous Month+1.23%Dollar Volume Sold Short$270.60 millionShort Interest Ratio1.8 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares98,280,000 sharesPercentage of Shares Shorted15.12%Today's Trading Volume6,705,505 sharesAverage Trading Volume5,878,008 sharesToday's Volume Vs. Average114% Short Selling Sarepta Therapeutics? Sign up to receive the latest short interest report for Sarepta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSRPT Short Interest Over TimeSRPT Days to Cover Over TimeSRPT Percentage of Float Shorted Over Time Sarepta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202514,860,000 shares $270.60 million +1.2%N/A1.8 $18.21 6/30/202514,680,000 shares $251.03 million +48.4%16.2%2.8 $17.10 6/15/20259,890,000 shares $357.82 million +6.8%10.9%2 $36.18 5/31/20259,260,000 shares $349.29 million +4.9%10.5%2.5 $37.72 5/15/20258,830,000 shares $311.43 million +31.8%10.0%2.6 $35.27 4/30/20256,700,000 shares $418.08 million +1.2%N/A2.5 $62.40 4/15/20256,620,000 shares $360.26 million +8.5%7.5%3.5 $54.42 3/31/20256,100,000 shares $389.30 million +25.8%6.9%3.7 $63.82 3/15/20254,850,000 shares $471.37 million -4.2%5.5%3.9 $97.19 2/28/20255,060,000 shares $540.16 million +2.9%5.7%6 $106.75 Get the Latest News and Ratings for SRPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/20254,920,000 shares $531.11 million -2.6%5.6%5.6 $107.95 1/31/20255,050,000 shares $574.29 million +1.4%N/A5.3 $113.72 1/15/20254,980,000 shares $594.26 million -2.9%N/A5.3 $119.33 12/31/20245,130,000 shares $623.76 million -8.2%N/A5.5 $121.59 12/15/20245,590,000 shares $691.54 million -4.0%N/A5.8 $123.71 11/30/20245,820,000 shares $776.04 million +15.5%N/A6 $133.34 11/15/20245,040,000 shares $526.88 million -10.0%N/A5.5 $104.54 10/31/20245,600,000 shares $705.60 million -1.1%N/A6.6 $126.00 10/15/20245,660,000 shares $700.31 million -8.6%N/A6 $123.73 9/30/20246,190,000 shares $773.07 million +0.7%N/A6.1 $124.89 9/15/20246,150,000 shares $766.60 million -5.8%N/A5.3 $124.65 8/31/20246,530,000 shares $886.64 million -3.0%N/A4.4 $135.78 8/15/20246,730,000 shares $897.38 million +0.2%N/A3.5 $133.34 7/31/20246,720,000 shares $955.85 million -8.3%N/A3.5 $142.24 7/15/20247,330,000 shares $1.12 billion -23.3%N/A3.9 $152.67 6/30/20249,560,000 shares $1.51 billion +1.1%N/A5.4 $158.00 6/15/20249,460,000 shares $1.16 billion +45.8%N/A5.7 $122.84 5/31/20246,490,000 shares $842.79 million -1.1%N/A5.1 $129.86 5/15/20246,560,000 shares $869.20 million +15.3%N/A7.3 $132.50 4/30/20245,690,000 shares $720.70 million +16.8%N/A6.2 $126.66 4/15/20244,870,000 shares $576.17 million +5.9%N/A5.8 $118.31 3/31/20244,600,000 shares $595.52 million -7.4%N/A4.5 $129.46 3/15/20244,970,000 shares $611.56 million +4.0%N/A4.6 $123.05 2/29/20244,780,000 shares $611.36 million -0.6%N/A4 $127.90 2/15/20244,810,000 shares $600.72 million -7.0%N/A4.1 $124.89 1/31/20245,170,000 shares $615.18 million -9.0%N/A4.1 $118.99 1/15/20245,680,000 shares $663.42 million +21.1%N/A3.2 $116.80 12/31/20234,690,000 shares $452.26 million -0.4%N/A2.7 $96.43 12/15/20234,710,000 shares $437.98 million +10.6%N/A2.9 $92.99 11/30/20234,260,000 shares $346.25 million +0.2%N/A2.8 $81.28[Warning] Buffett Indicator hits new All-Time-High (Ad)Warren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullish for stocks. In fact, the last three times this happened, a major market pullback followed… and gold entered a decade-long bull run. If history’s any guide, the smartest move today could be positioning in gold—specifically, a handful of high-potential developers.See the four gold stocks best positioned to benefit. 11/15/20234,250,000 shares $355.98 million -4.5%N/A2.9 $83.76 10/31/20234,450,000 shares $299.53 million -8.8%N/A3 $67.31 10/15/20234,880,000 shares $575.64 million +1.2%N/A5.4 $117.96 9/30/20234,820,000 shares $584.28 million +6.6%N/A5.2 $121.22 9/15/20234,520,000 shares $535.17 million -2.0%N/A4.6 $118.40 8/31/20234,610,000 shares $557.86 million +4.1%N/A4.3 $121.01 8/15/20234,430,000 shares $505.37 million -0.5%N/A3.8 $114.08 7/31/20234,450,000 shares $482.34 million -9.9%N/A3.2 $108.39 7/15/20234,940,000 shares $532.70 million -1.0%N/A3.5 $107.84 6/30/20234,990,000 shares $571.45 million +9.7%N/A3.3 $114.52 6/15/20234,550,000 shares $598.83 million +2.9%N/A3.1 $131.61 5/31/20234,420,000 shares $546.31 million +17.9%N/A2.8 $123.60 5/15/20233,750,000 shares $589.46 million -8.5%N/A2.2 $157.19 4/30/20234,100,000 shares $503.36 million -8.5%N/A2.8 $122.77 4/15/20234,480,000 shares $549.38 million -5.1%N/A3.1 $122.63 3/31/20234,720,000 shares $650.56 million -13.2%N/A3.4 $137.83 3/15/20235,440,000 shares $791.36 million -32.7%N/A4 $145.47 2/28/20238,080,000 shares $986.81 million +7.0%N/A7.1 $122.13 2/15/20237,550,000 shares $941.64 million +12.4%N/A8.1 $124.72 1/31/20236,720,000 shares $839.80 million +8.9%N/A7.3 $124.97 1/15/20236,170,000 shares $781.74 million -9.8%N/A6.5 $126.70 12/30/20226,840,000 shares $886.33 million -1.0%N/A7.3 $129.58 12/15/20226,910,000 shares $861.33 million -1.0%N/A7.5 $124.65 11/30/20226,980,000 shares $857.21 million -5.0%N/A6.5 $122.81 11/15/20227,350,000 shares $806.15 million -8.6%N/A7.2 $109.68 10/31/20228,040,000 shares $916.72 million +11.1%N/A7.5 $114.02 10/15/20227,240,000 shares $814.14 million -1.4%N/A6.4 $112.45 9/30/20227,340,000 shares $811.36 million +7.6%N/A6.7 $110.54 9/15/20226,820,000 shares $754.84 million +4.1%N/A6 $110.68 8/31/20226,550,000 shares $716.44 million -4.5%N/A6.7 $109.38 8/15/20226,860,000 shares $748.01 million +34.3%N/A7.2 $109.04 7/31/20225,110,000 shares $474.97 million -4.7%N/A5.5 $92.95 7/15/20225,360,000 shares $448.04 million +2.7%N/A6.8 $83.59 6/30/20225,220,000 shares $391.29 million +4.8%N/A6.7 $74.96 6/15/20224,980,000 shares $321.21 million -0.4%N/A6.7 $64.50 5/31/20225,000,000 shares $364.10 million -2.0%N/A7 $72.82 5/15/20225,100,000 shares $336.45 million +5.6%N/A6.7 $65.97 4/30/20224,830,000 shares $349.31 million -1.2%N/A6.6 $72.32 4/15/20224,890,000 shares $398.29 million -5.4%N/A6.2 $81.45 3/31/20225,170,000 shares $403.88 million -2.5%N/A5.2 $78.12 3/15/20225,300,000 shares $403.70 million -1.1%N/A5.4 $76.17 2/28/20225,360,000 shares $410.63 million -2.2%N/A5.4 $76.61 2/15/20225,480,000 shares $445.80 million -6.8%N/A5.6 $81.35 1/31/20225,880,000 shares $420.83 million +30.1%N/A5.8 $71.57 1/15/20224,520,000 shares $321.37 million -1.3%N/A4.3 $71.10 12/31/20214,580,000 shares $412.43 million -15.0%N/A4.4 $90.05 12/15/20215,390,000 shares $470.71 million -1.1%N/A5.2 $87.33 11/30/20215,450,000 shares $440.41 million +16.5%N/A5.2 $80.81 11/15/20214,680,000 shares $392.56 million +2.0%N/A4.7 $83.88 10/29/20214,590,000 shares $363.21 million -8.8%N/A4.7 $79.13[Warning] Buffett Indicator hits new All-Time-High (Ad)Warren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullish for stocks. In fact, the last three times this happened, a major market pullback followed… and gold entered a decade-long bull run. If history’s any guide, the smartest move today could be positioning in gold—specifically, a handful of high-potential developers.See the four gold stocks best positioned to benefit. 10/15/20215,030,000 shares $423.48 million -0.2%N/A5.3 $84.19 9/30/20215,040,000 shares $466.10 million -11.0%6.7%6 $92.48 9/15/20215,660,000 shares $475.72 million -3.6%7.5%7.3 $84.05 8/31/20215,870,000 shares $458.56 million -5.0%7.8%7.5 $78.12 8/13/20216,180,000 shares $494.03 million -2.4%8.2%6.7 $79.94 7/30/20216,330,000 shares $429.05 million -2.5%8.3%6 $67.78 7/15/20216,490,000 shares $443.72 million +0.8%8.5%5.9 $68.37 6/30/20216,440,000 shares $500.65 million -3.3%8.5%5.9 $77.74 6/15/20216,660,000 shares $553.71 million -16.7%8.8%5.8 $83.14 5/28/20217,990,000 shares $604.44 million +4.0%10.5%6.9 $75.65 5/14/20217,680,000 shares $556.88 million +8.0%N/A6.6 $72.51 4/30/20217,110,000 shares $507.73 million -2.2%N/A6.3 $71.41 4/15/20217,270,000 shares $533.84 million -0.7%N/A6.3 $73.43 3/31/20217,320,000 shares $535.09 million +7.3%N/A3.5 $73.10 3/15/20216,820,000 shares $589.73 million -6.8%N/A3.3 $86.47 2/26/20217,320,000 shares $624.03 million +8.9%N/A3.6 $85.25 2/12/20216,720,000 shares $609.97 million -13.3%N/A3.6 $90.77 1/29/20217,750,000 shares $698.51 million -4.3%N/A4.1 $90.13 1/15/20218,100,000 shares $728.19 million +14.6%N/A4.6 $89.90 12/31/20207,070,000 shares $1.21 billion -10.6%N/A5 $171.54 12/15/20207,910,000 shares $1.34 billion -9.1%N/A11.3 $169.54 11/30/20208,700,000 shares $1.21 billion +5.2%N/A12.7 $139.15 11/15/20208,270,000 shares $1.17 billion -6.2%N/A11.6 $141.40 10/30/20208,820,000 shares $1.25 billion -0.6%N/A12.1 $141.49 10/15/20208,870,000 shares $1.29 billion -2.9%N/A13.5 $145.12 9/30/20209,130,000 shares $1.28 billion +0.7%N/A13.1 $140.43 9/15/20209,070,000 shares $1.30 billion -4.1%N/A12.5 $142.80 8/31/20209,460,000 shares $1.39 billion -3.2%N/A12 $146.42 8/14/20209,770,000 shares $1.53 billion -3.0%N/A11.7 $157.00 SRPT Short Interest - Frequently Asked Questions What is Sarepta Therapeutics' current short interest? Short interest is the volume of Sarepta Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 14,860,000 shares of SRPT short. Learn More on Sarepta Therapeutics' current short interest. What is a good short interest ratio for Sarepta Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SRPT shares currently have a short interest ratio of 2.0. Learn More on Sarepta Therapeutics's short interest ratio. Which institutional investors are shorting Sarepta Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Sarepta Therapeutics: Wolverine Asset Management LLC, Sivik Global Healthcare LLC, Quaker Wealth Management LLC, Jane Street Group LLC, Goldman Sachs Group Inc., Parallax Volatility Advisers L.P., Royal Bank of Canada, Nomura Holdings Inc., Twin Tree Management LP, PEAK6 LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, Garda Capital Partners LP, JPMorgan Chase & Co., Wolverine Asset Management LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Sarepta Therapeutics' short interest increasing or decreasing? Sarepta Therapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 14,860,000 shares, an increase of 1.2% from the previous total of 14,680,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Sarepta Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Sarepta Therapeutics: CytomX Therapeutics, Inc. (29.61%), Editas Medicine, Inc. (10.18%), Lantheus Holdings, Inc. (12.25%), Axsome Therapeutics, Inc. (7.37%), Vaxcyte, Inc. (10.56%), Merus N.V. (6.56%), Krystal Biotech, Inc. (10.87%), Cytokinetics, Incorporated (13.64%), Zai Lab Limited Unsponsored ADR (3.58%), ADMA Biologics Inc (6.06%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Sarepta Therapeutics stock? Short selling SRPT is an investing strategy that aims to generate trading profit from Sarepta Therapeutics as its price is falling. SRPT shares are trading down $0.82 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sarepta Therapeutics? A short squeeze for Sarepta Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SRPT, which in turn drives the price of the stock up even further. How often is Sarepta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SRPT, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies CTMX Short Interest EDIT Short Interest LNTH Short Interest AXSM Short Interest PCVX Short Interest MRUS Short Interest KRYS Short Interest CYTK Short Interest ZLAB Short Interest ADMA Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SRPT) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
